Albany Molecular Research (AMRI), a global contract research and manufacturing organisation, has appointed Michael Nolan as vice president, chief financial officer (CFO) and treasurer, succeeding Mark Frost.
Nolan was most recently vice president, finance, financial planning and analysis at the Delaware North Companies. From 2009 through early 2012, he was vice president, finance, analytical instruments group at Thermo Fisher Scientific, where he was responsible for the global financial operations of a portfolio with revenue of US$3bn operating across three divisions with 15 business units, 41 plant sites and 9,700 employees.
Prior to Thermo Fisher Scientific, Nolan held positions of increasing responsibility at ALCAN, which was later acquired by Rio Tinto. While at Rio Tinto, he was accountable for leading the integration of 13 global ALCAN and Rio Tinto functions, including legal, company secretarial, business development and all finance functions including both the corporate and business teams.
Nolan began his career in 1989 at EI du Pont de Nemours and received his MBA from The University of Windsor and a BA in Economics from The University of Western Ontario.
A report by broking group Marsh examines the repercussions from the administration of the South Korean company, which filed for bankruptcy protection at the end of August.
Global research by C2FO suggests that smaller businesses are less concerned with the repercussions of Brexit and the upcoming US presidential election.
A squeeze on skilled talent means it now takes an average of seven weeks to fill open permanent roles in finance in the UK according to new research from financial services recruitment firm Robert Half.
Early-stage merger and acquisition deals in Asia-Pacific show nearly 10% year-on-year growth in recent months.